From Leaping Leo to the Big Dipper: Here's how to see the bright stars of spring rising in the east this season
When you buy through links on our articles, Future and its syndication partners may earn a commission.
The constellations march ever westward from month to month, with old ones disappearing into the sunset as new ones rise in the east.
This is because the stars run like clockwork on a specific schedule. Thanks to the fact that our Earth rotates on its axis once every 23 hours and 56 minutes, a star — any star — rises and sets four minutes earlier every day than it did the day before. This motion means that any given array of constellations will appear in the same location of the sky two hours earlier each month. So, the celestial scene you witnessed by staying up until 11 p.m. in mid-April is already there at dusk in mid-May.
At this time of year, as the last of the bright patterns of winter decline in the west, the milder stars of spring have ascended to dominate our southern and eastern skies. For those of us living in the cities, surrounded by smoke and haze and bright lights, it becomes easy to overlook the beauty of the night. For seldom do we travel out into the country, far from the lights of humanity to enjoy this grandeur.
Our distant ancestors, however, had no such concerns; they could see the sky at night perfectly from wherever they were. Their imaginations were not weakened by pictures in newspapers and magazines, movies or television. The night sky provided their sole entertainment, and they weaved stories filled with imagination, using patterns of stars for illustration.
These patterns — the constellations — are the legacy of their imagination; the constellations that we know have their origins in the eastern Mediterranean and the Middle East, thanks to the ancient Greeks and Romans. These constellations (plus some modern ones) are now accepted everywhere in the West.
But what about traditional cultures in the rest of the world? Interestingly, the night sky contains a number of star patterns so striking that almost every culture in the world has recognized them. Several of them occupy our current spring sky. Probably the most famous is positioned almost directly over our heads this week as darkness falls: the Big Dipper.
Officially, the Dipper is not a full-fledged constellation, but an asterism — just a part of the constellation known as Ursa Major, the Great Bear. And indeed, Ursa Major is a big bear. Along with the seven stars that compose the Big Dipper, its surrounding stars sprawl across a whole quadrant of the sky. In area it's the third biggest constellation, behind Hydra the Water Snake and Virgo the Maiden.
Interestingly, the ancient Greeks associated the seven stars of the Big Dipper with a bear long before they added the surrounding stars to complete the picture of a ferocious animal with a head and paws some two millennia ago. But what made the Greeks think of a bear? The Dipper's handle must be the bear's long tail, yet bears possess short, stubby tails.
TOP TELESCOPE PICK:
See the night sky up close with the Celestron NexStar 4SE, an ideal telescope for beginners wanting quality, reliable and quick views of celestial objects. For a more in-depth look at our Celestron NexStar 4SE review.
The ancient Greek philosopher Aristotle (384-322 BC) believed that the bear was the only animal that could survive in the frigid north — indeed, our word "arctic" is derived from arctos, which is Greek for "bear." By this logic, only a bear could inhabit the northern sky.
We can use the Big Dipper to find other familiar stars and constellations currently adorning our springtime sky. The two stars forming the outer end of the Dipper's bowl, are known as the "pointer" stars and currently point straight down toward Polaris, the North Star, which is due north. The aim isn't perfect but close enough. Polaris marks the end of the tail of Ursa Minor the Little Bear, or the handle of the Little Dipper, whose stars are quite faint, except the North Star and the two in the front of its bowl; these have been called the "Guardians" because they seem to march endlessly, like sentries circling the pole.
At New York's Hayden Planetarium, we would ask our audiences to imagine that the bowl of the Dipper was filled with water. "Now, imagine if we poked a hole in the bottom of the bowl and let the water spill out. Who would get wet?" With our electric pointer, we'd then follow the imaginary flow of water down to a pattern of stars composed of a triangle and a backward question mark shape that's about 1½ fist-widths at arm's length tall. This is the "Sickle" that marks the head and mane of Leo the Lion.
The Sickle is a landmark of the spring skies; it's composed of six stars, the brightest of these is Regulus, a blue-white first magnitude star, 79 light years away which marks the base of the Sickle. The pointer stars of the Big Dipper point in one direction to the North Star; in the other direction to the triangle that makes up the lion's hind quarters and tail.
Going back to the Big Dipper, if we follow the curve of the Dipper's handle past its end star for about 30 degrees ("three fists"), you'll come to a brilliant star — in rank, the fourth brightest in the sky — which shines with a distinct orange hue known as Arcturus, in Boötes the Herdsman. The other stars of Boötes are much fainter, of third and fourth magnitude. Most of them form a kite-shaped figure extending close to the Dipper's handle, although my personal preference is to visualize Boötes as an ice cream cone.
Arcturus (at a magnitude of -0.05), one of the few stars mentioned by name in the Bible, is a giant, about 25 times the diameter of our sun and 36.7 light years away. Boötes is chasing the Bears with a pair of Hunting Dogs (Canes Venatici), which makes a small constellation between Arcturus and the Dipper's bowl.
If we continue to follow the arc of the Big Dipper's handle past Arcturus, we eventually will "speed to Spica," the brightest star of Virgo the Maiden. Spica is a blue-white first magnitude star 250 light-years away.
The year 2026 marks the 250th anniversary of the United States; it is interesting to note that the light from Spica that started on its journey toward Earth at the time that the Declaration of Independence was ratified in 1776, will finally arrive next year.
More night sky:
— Night sky for tonight: Visible planets, stars and more in this evening's sky
— Night sky, May 2025: What you can see tonight [maps]
— Best stargazing apps 2025: AR apps and virtual star maps to help you navigate the night sky
Just to the right of Spica, the most striking star pattern in the spring skies next to Leo's Sickle is a little four-sided figure of fairly bright stars, resembling a triangle whose top has been removed by a slanting cut. Like most of the constellations it bears little resemblance to the object it is supposed to represent: Corvus the Crow.
Just follow the direction of its slanting top toward the left (east) and you will soon comet to Spica. In the old allegorical star atlases, Virgo is holding a spike of wheat where Spica glows, evidently representing the harvest time which occurs in mid-October when the sun is passing that bright star. And apparently, Corvus is lying in wait to snatch the wheat from out of Virgo's hand!
At least that's the story.
At this time of the year, eleven first magnitude stars are in the sky simultaneously as the sky darkens. Brilliant Sirius, a winter luminary and the brightest of all the stars, is disappearing in the west-southwest, while Deneb, a star of the summer season, is just beginning to peek above the north-northeast horizon. And our spring evening sky is also augmented with two bright planets. Low in the west-northwest is brilliant Jupiter, which will remain in view for another few weeks before it vanishes into the bright evening twilight.
And much higher in the southwest sky glows Mars. Currently located against the dim stars of Cancer, on June 17 — just a few days shy of the official end of spring — it will call attention to itself in the west after dusk by forming a striking "double star" with Regulus. The planet will be just a trifle dimmer than the star but their proximity intensifies the orange-yellow of Mars and the blue-white of Regulus.
Joe Rao serves as an instructor and guest lecturer at New York's Hayden Planetarium. He writes about astronomy for Natural History magazine, Sky and Telescope and other publications.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
31 minutes ago
- Gizmodo
New Russian Satellite Appears to Be Stalking U.S. Satellite in Orbit
A recently launched Russian satellite is getting uncomfortably cozy with a U.S. reconnaissance satellite, leading Space Command to worry that it's part of an anti-satellite weapon being deployed to orbit. Cosmos 2588 launched on May 23 to a near-circular orbit, placing it eerily close to a U.S. reconnaissance satellite, USA 338. The move prompted suspicion that it's an attempt by Russia to deliberately stalk the U.S. government satellite. This isn't the first time Russia has deployed a sneaky satellite to trail behind and allegedly observe another satellite in orbit, but this time it may be connected to Russia's controversial anti-satellite program. 'U.S. Space Command can confirm Russia's recent launch put a Russian satellite into an orbit near a U.S. government satellite,' a Space Command spokesperson is quoted as saying to Breaking Defense. 'Russia continues to research, develop, test, and deploy a suite of counter space systems that threaten the safety and the stability of the domain, so consistent with all on-orbit objects, USSPACECOM will continue to monitor for concerning behavior or activity related to this launch.' Slingshot Aerospace reports that the alleged spy satellite, Cosmos 2588, is a NIVELIR military inspection satellite likely carrying a kinetic weapon onboard. Its alignment with USA 338 'strongly suggests COSMOS 2588 may be actively monitoring or 'chasing' it,' the satellite tracking company wrote in a statement. Slingshot Aerospace has been tracking the two satellites, revealing that Cosmos 2588 is orbiting at a slightly higher altitude and that the two objects will have a close flyby of one another roughly every four days. The two satellites come as close as 62 miles (100 kilometers) from one another, Marco Langbroek, an astronomer and expert on space situational awareness at the Delft University of Technology in the Netherlands, wrote on X. Not much else is known about USA 338 as it doesn't have publicly available orbital data, but it is believed to be a part of the National Reconnaissance Office's KH-series electro-optical surveillance network, known as the Crystal constellation, according to Interesting Engineering. This isn't the first time Russia has allegedly deployed a satellite for such a purpose. In April 2023, a Russian satellite appeared to be closely trailing a classified U.S. military satellite, and Russia's Kosmos 2558, launched in August 2022, was deployed into the same orbital plane as a U.S. military satellite, dubbed USA 326. In 2020, another Russian satellite, Kosmos 2542, stalked USA 245, an electro-optical spy satellite in low Earth orbit. The U.S. isn't completely innocent either. In June 2017, classified U.S. military satellite USA 276 snuck up on the International Space Station at a close distance of about 4 miles (6.4 kilometers). Earlier in 1998, hobbyists discovered a U.S. satellite that was believed to have been used for space spying purposes as well. Russia's satellites, however, are believed to be part of the country's efforts to develop an anti-satellite weapon designed to destroy other objects in space. In November 2021, Russia destroyed a defunct Soviet-era satellite in low Earth orbit, producing thousands of pieces of orbital debris. The test prompted the United Nations to draft a resolution against tests of anti-satellite (ASAT) missile systems, which was led by the Biden administration after the U.S. adopted a self-imposed ban on ASAT tests. A total of 155 countries voted in favor of the resolution, while nine voted against it, including Russia, China, Cuba, Syria, and Iran. 'This is the fourth time in five years that they launch a satellite into a coplanar orbit with a US optical reconnaissance satellite,' Langbroek wrote on X. 'So no, not mere coincidence but deliberate.'


Medscape
31 minutes ago
- Medscape
Fact or Fiction: Ovarian Cancer and Drug Resistance
In ovarian cancer, the emergence of drug resistance has been shown to limit the durability of therapeutic treatment benefit and contribute substantially to ovarian cancer's high mortality rate. Factors such as treatment-free intervals and tumor microevolution may allow for re-sensitization to platinum agents in select patients. In addition to tumor biology, the tumor microenvironment plays a pivotal role in therapeutic resistance. Targeted therapies, once heralded as a solution to chemotherapy resistance, have been shown to face similar obstacles. Drug resistance in ovarian cancer management is an ongoing field of study as clinicians look to limit its impact improve outcomes. Platinum resistance in ovarian cancer is not always permanent. While many patients relapse with tumors less responsive to platinum-based chemotherapy, resistance can be dynamic. Mechanisms such as epigenetic alterations, modulation of DNA damage response, and temporary activation of drug efflux pumps may contribute to reversible resistance. Importantly, a subset of patients initially labeled as platinum-resistant may benefit from platinum rechallenge after a treatment-free interval, particularly if newer maintenance strategies or resensitizing agents are used. This has led to the concept of a "platinum-free interval" to help guide re-treatment. Understanding these nuances is crucial for tailoring treatment strategies and optimizing outcomes. Learn more about medications used in ovarian cancer. While HRD — often due to BRCA1/2 mutations — initially predicts strong sensitivity to DNA-damaging therapies like platinum agents and PARP inhibitors, resistance commonly emerges over time. A key mechanism is the restoration of homologous recombination through secondary or "reversion" mutations in HR pathway genes. These mutations enable tumor cells to resume high-fidelity DNA repair, diminishing the cytotoxic effects of therapy. Additionally, tumors may activate compensatory pathways such as non-homologous end joining or increase drug efflux activity. This resistance may not be detectable at diagnosis and can evolve under therapeutic pressure. Consequently, current research emphasizes longitudinal molecular monitoring to capture evolving resistance mechanisms. Clinically, this underscores the need for re-biopsy or circulating tumor DNA analysis to reassess HR status in recurrent disease, which may influence therapy selection. Learn more about the importance of biopsy in ovarian cancer. Tumor heterogeneity — both genetic and phenotypic — plays a central role in drug resistance and further complications treatment outcomes. Ovarian tumors often consist of diverse subclonal populations, some of which may possess innate resistance traits. Within a single ovarian tumor, multiple subclonal populations may coexist, each with distinct characteristics and sensitivity profiles. When systemic therapy is applied, sensitive clones are eliminated, but resistant ones may persist and expand. Single-cell and spatial transcriptomics studies have mapped how this clonal evolution occurs, revealing that treatment can select for resistant subpopulations not evident at baseline. Heterogeneity also affects the tumor microenvironment and immune response, further complicating therapeutic strategies. Clinically, this variability can manifest as mixed responses, where some lesions regress while others progress. Addressing heterogeneity remains a major challenge and has sparked interest in combination therapies and adaptive trial designs. Personalized treatment strategies based on real-time tumor profiling are likely to improve outcomes by accounting for this complexity. Learn more about ovarian cancer guidelines. Targeted therapies are susceptible to various resistance mechanisms, many of which overlap with those seen in chemotherapy. For example, resistance to PARP inhibitors, widely used in HRD-positive ovarian cancers, can arise from secondary mutations restoring DNA repair function or through enhanced drug efflux. Similarly, resistance to angiogenesis inhibitors may develop via upregulation of alternative pro-angiogenic pathways or changes in tumor vasculature that circumvent the need for VEGF signaling. Resistance is further complicated by factors such as epigenetic reprogramming and altered cell signaling networks. These findings have led to interest in combining targeted agents with immune checkpoint inhibitors, DNA repair modulators, or epigenetic therapies to overcome resistance. Future success with targeted therapy will likely depend on combination approaches informed by tumor genomics and adaptive resistance profiling. Learn more about risk assessment and genetic counseling in ovarian cancer. The tumor microenvironment (TME) is a key contributor to drug resistance in ovarian cancer. Immune cells such as regulatory T cells and tumor-associated macrophages (TAMs) create an immunosuppressive milieu that hinders effective therapy. Additionally, fibroblasts and extracellular matrix components can form physical barriers that limit drug penetration. Cytokines and growth factors secreted within the TME also modulate signaling pathways in tumor cells, promoting survival and resistance. Studies have shown that high TAM density is associated with poor response to both chemotherapy and immunotherapy, and interventions targeting the TME may help reverse resistance. This includes strategies like macrophage reprogramming, TME remodeling agents, and stromal-targeting therapies. Incorporating TME characteristics into clinical decision-making may help guide therapeutic combinations and predict response. Learn more about tumor biomarkers in ovarian cancer.


The Verge
36 minutes ago
- The Verge
Here's what's inside Meta's experimental new AR glasses
Meta has revealed more information about Aria Gen 2, its experimental smart glasses designed to serve as a test platform for research about augmented reality, AI, and robotics. The glasses pack several improvements into their lightweight frame that could one day translate into consumer products, including an improved eye-tracking system that can track gaze per eye, detect blinks, and estimate the center of pupils. 'These advanced signals enable a deeper understanding of the wearer's visual attention and intentions, unlocking new possibilities for human-computer interaction,' Meta writes. Meta initially announced Aria Gen 2 in February, saying they will 'pave the way for future innovations that will shape the next computing platform.' They build upon Meta's first iteration of the glasses in 2020, which were similarly available for researchers only. Along with an improved eye-tracking system, Aria Gen 2 comes with four computer vision cameras that Meta says enable 3D hand and object tracking. Meta says researchers can use this information to enable highly precise tasks like 'dexterous robot hand manipulation.' The glasses also have a photoplethysmography sensor built into the nosepad, which allows the device to estimate a wearer's heart rate, along with a contact microphone that Meta says provides better audio in loud environments. There's a new ambient light sensor as well, allowing the glasses to differentiate between indoor and outdoor lighting. The Aria Gen 2 glasses include folding arms for the first time, weigh around 75 grams, and come in eight different sizes. Meta plans on opening applications for researchers to work with Aria Gen 2 later this year. The initiative builds on the successful development of Meta's Ray-Ban smart glasses, a form factor it aims to expand with its Orion augmented-reality glasses, a rumored partnership with Oakley, and a high-end pair of 'Hypernova' glasses with a built-in screen.